Complement 3 Glomerulopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major complement 3 glomerulopathy markets reached a value of US$ 9.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.8 Billion by 2034, exhibiting a growth rate (CAGR) of 2.46% during 2024-2034.
The complement 3 glomerulopathy market has been comprehensively analyzed in IMARC's new report titled "Complement 3 Glomerulopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Complement 3 glomerulopathy (C3G) is a rare kidney disorder characterized by the abnormal deposition of complement component C3 in the glomeruli of the kidney. The complement system is an integral part of the immune system that helps protect the body from infection and other threats. Some of the common symptoms of C3G are hematuria, which is the presence of blood in the urine, and proteinuria, which is distinguished by an abundance of protein in the urine. Various other indications include edema, hypertension, renal impairment, etc. The diagnosis of complement 3 glomerulopathy requires a combination of clinical evaluation, laboratory investigations, and imaging studies. Several urine tests, such as urinalysis and urine protein-to-creatinine ratio, are used to identify the presence and severity of proteinuria and hematuria. In addition to this, various blood tests, including serum creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), etc., are conducted to assess renal function. The gold standard for diagnosis is kidney biopsy, which entails obtaining a tiny sample of kidney tissue and studying it under a microscope to see whether C3 deposits are present in the glomeruli. Besides this, complement activity assays, imaging studies, immunofluorescence staining, and genetic testing can also aid in diagnosing C3G.
The increasing prevalence of autoimmune diseases and the growing need for therapeutics that can efficiently treat the symptoms and slow the progression of the ailment are primarily driving the complement 3 glomerulopathy market. In addition to this, the rising usage of immunosuppressive medications, including corticosteroids, cyclophosphamide, mycophenolate mofetil, etc., to reduce inflammation is also creating a positive outlook for the market. Moreover, the emerging popularity of combination therapies over single-agent therapies on account of their several associated benefits, such as tailored treatment to individual patient needs and reduced risk of side effects, is also augmenting the market growth. Apart from this, the widespread adoption of complement inhibitors, which selectively block the activity of the complement system, a vital part of the immune system involved in the development of C3G, for treating the ailment is further propelling the market growth. Additionally, numerous key players are exploring the use of biomarkers that can aid in identifying specific molecular or genetic characteristics of patients for personalizing the treatment to their particular needs. This, in turn, is acting as another significant growth-inducing factor. Furthermore, ongoing advancements in the field of diagnostics, including the introduction of immunofluorescence staining for identifying the deposition of complement component C3 in the glomeruli of the kidney, are expected to drive the complement 3 glomerulopathy market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the complement 3 glomerulopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for complement 3 glomerulopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the complement 3 glomerulopathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the complement 3 glomerulopathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the complement 3 glomerulopathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current complement 3 glomerulopathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the complement 3 glomerulopathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the complement 3 glomerulopathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the complement 3 glomerulopathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of complement 3 glomerulopathy across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of complement 3 glomerulopathy by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of complement 3 glomerulopathy by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of complement 3 glomerulopathy by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with complement 3 glomerulopathy across the seven major markets?
What is the size of the complement 3 glomerulopathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of complement 3 glomerulopathy?
What will be the growth rate of patients across the seven major markets?
Complement 3 Glomerulopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for complement 3 glomerulopathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the complement 3 glomerulopathy market?
What are the key regulatory events related to the complement 3 glomerulopathy market?
What is the structure of clinical trial landscape by status related to the complement 3 glomerulopathy market?
What is the structure of clinical trial landscape by phase related to the complement 3 glomerulopathy market?
What is the structure of clinical trial landscape by route of administration related to the complement 3 glomerulopathy market?
The complement 3 glomerulopathy market has been comprehensively analyzed in IMARC's new report titled "Complement 3 Glomerulopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Complement 3 glomerulopathy (C3G) is a rare kidney disorder characterized by the abnormal deposition of complement component C3 in the glomeruli of the kidney. The complement system is an integral part of the immune system that helps protect the body from infection and other threats. Some of the common symptoms of C3G are hematuria, which is the presence of blood in the urine, and proteinuria, which is distinguished by an abundance of protein in the urine. Various other indications include edema, hypertension, renal impairment, etc. The diagnosis of complement 3 glomerulopathy requires a combination of clinical evaluation, laboratory investigations, and imaging studies. Several urine tests, such as urinalysis and urine protein-to-creatinine ratio, are used to identify the presence and severity of proteinuria and hematuria. In addition to this, various blood tests, including serum creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), etc., are conducted to assess renal function. The gold standard for diagnosis is kidney biopsy, which entails obtaining a tiny sample of kidney tissue and studying it under a microscope to see whether C3 deposits are present in the glomeruli. Besides this, complement activity assays, imaging studies, immunofluorescence staining, and genetic testing can also aid in diagnosing C3G.
The increasing prevalence of autoimmune diseases and the growing need for therapeutics that can efficiently treat the symptoms and slow the progression of the ailment are primarily driving the complement 3 glomerulopathy market. In addition to this, the rising usage of immunosuppressive medications, including corticosteroids, cyclophosphamide, mycophenolate mofetil, etc., to reduce inflammation is also creating a positive outlook for the market. Moreover, the emerging popularity of combination therapies over single-agent therapies on account of their several associated benefits, such as tailored treatment to individual patient needs and reduced risk of side effects, is also augmenting the market growth. Apart from this, the widespread adoption of complement inhibitors, which selectively block the activity of the complement system, a vital part of the immune system involved in the development of C3G, for treating the ailment is further propelling the market growth. Additionally, numerous key players are exploring the use of biomarkers that can aid in identifying specific molecular or genetic characteristics of patients for personalizing the treatment to their particular needs. This, in turn, is acting as another significant growth-inducing factor. Furthermore, ongoing advancements in the field of diagnostics, including the introduction of immunofluorescence staining for identifying the deposition of complement component C3 in the glomeruli of the kidney, are expected to drive the complement 3 glomerulopathy market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the complement 3 glomerulopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for complement 3 glomerulopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the complement 3 glomerulopathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the complement 3 glomerulopathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the complement 3 glomerulopathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current complement 3 glomerulopathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the complement 3 glomerulopathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the complement 3 glomerulopathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the complement 3 glomerulopathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of complement 3 glomerulopathy across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of complement 3 glomerulopathy by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of complement 3 glomerulopathy by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of complement 3 glomerulopathy by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with complement 3 glomerulopathy across the seven major markets?
What is the size of the complement 3 glomerulopathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of complement 3 glomerulopathy?
What will be the growth rate of patients across the seven major markets?
Complement 3 Glomerulopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for complement 3 glomerulopathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the complement 3 glomerulopathy market?
What are the key regulatory events related to the complement 3 glomerulopathy market?
What is the structure of clinical trial landscape by status related to the complement 3 glomerulopathy market?
What is the structure of clinical trial landscape by phase related to the complement 3 glomerulopathy market?
What is the structure of clinical trial landscape by route of administration related to the complement 3 glomerulopathy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 COMPLEMENT 3 GLOMERULOPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 COMPLEMENT 3 GLOMERULOPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 COMPLEMENT 3 GLOMERULOPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 COMPLEMENT 3 GLOMERULOPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 COMPLEMENT 3 GLOMERULOPATHY - UNMET NEEDS
10 COMPLEMENT 3 GLOMERULOPATHY - KEY ENDPOINTS OF TREATMENT
11 COMPLEMENT 3 GLOMERULOPATHY - MARKETED PRODUCTS
11.1 List of Complement 3 Glomerulopathy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 COMPLEMENT 3 GLOMERULOPATHY - PIPELINE DRUGS
12.1 List of Complement 3 Glomerulopathy Pipeline Drugs Across the Top 7 Markets
12.1.1 Iptacopan - Novartis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 KP104 - Kira Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 AMY-101 - Amyndas Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ARO-C3 - Arrowhead Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. COMPLEMENT 3 GLOMERULOPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. COMPLEMENT 3 GLOMERULOPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 COMPLEMENT 3 GLOMERULOPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Complement 3 Glomerulopathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Complement 3 Glomerulopathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Complement 3 Glomerulopathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Complement 3 Glomerulopathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Complement 3 Glomerulopathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Complement 3 Glomerulopathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Complement 3 Glomerulopathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Complement 3 Glomerulopathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
16 COMPLEMENT 3 GLOMERULOPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 COMPLEMENT 3 GLOMERULOPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 COMPLEMENT 3 GLOMERULOPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 COMPLEMENT 3 GLOMERULOPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 COMPLEMENT 3 GLOMERULOPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 COMPLEMENT 3 GLOMERULOPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 COMPLEMENT 3 GLOMERULOPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 COMPLEMENT 3 GLOMERULOPATHY - UNMET NEEDS
10 COMPLEMENT 3 GLOMERULOPATHY - KEY ENDPOINTS OF TREATMENT
11 COMPLEMENT 3 GLOMERULOPATHY - MARKETED PRODUCTS
11.1 List of Complement 3 Glomerulopathy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 COMPLEMENT 3 GLOMERULOPATHY - PIPELINE DRUGS
12.1 List of Complement 3 Glomerulopathy Pipeline Drugs Across the Top 7 Markets
12.1.1 Iptacopan - Novartis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 KP104 - Kira Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 AMY-101 - Amyndas Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ARO-C3 - Arrowhead Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. COMPLEMENT 3 GLOMERULOPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. COMPLEMENT 3 GLOMERULOPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 COMPLEMENT 3 GLOMERULOPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Complement 3 Glomerulopathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Complement 3 Glomerulopathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Complement 3 Glomerulopathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Complement 3 Glomerulopathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Complement 3 Glomerulopathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Complement 3 Glomerulopathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Complement 3 Glomerulopathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Complement 3 Glomerulopathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Complement 3 Glomerulopathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Complement 3 Glomerulopathy - Access and Reimbursement Overview
16 COMPLEMENT 3 GLOMERULOPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 COMPLEMENT 3 GLOMERULOPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 COMPLEMENT 3 GLOMERULOPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
